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OBJECTIVES:The first objective was to assess the two-year changes in quality of life
after gastric bypass in patients with severe obesity. Second, we analysed the effect
of weight reduction on the different HRQL dimensions in the framework of the
International Classification of Functioning, Disability and Health (ICF). METHODS:
We carried out a prospective intervention study with consecutive patients referred
to two bariatric surgical units in the Basque Country. We included generic (SF-36,
EuroQuol 5D) and specific questionnaires (Moorehead-Ardelt, Obesity-related
Problems scale). The SF-36 mental and physical dimensions and stigma theory,
allowed us to apply an approach based on the ICF. We measured effect size (ES),
standardized response mean (SRM) and ROC curves. RESULTS: Of 82 operated pa-
tients, 79 were tracked for 2 years. Average weight loss was 49 kg (28%) and BMI was
reduced from 50.6 to 31.8. The initial problems and the final improvements were
larger in the physical dimensions. The benefit of treatment was large for almost all
HRQL domains as measured by EQ-5D, SF-36, OP and Moorehead-Ardelt. Only the
improvements in some of the mental domains of the SF-36 were classified as small
or moderate. ROC curves were not sensitive to change in BMI. CONCLUSIONS: We
suggest that the negative impact of severe obesity on HRQL is mainly a cause of
disability as described in the ICF. Two-year improvements in HRQL are related to
recovery from disability after gastric bypass treatment. The primary focus on the
physical dimension is not contradictory with evidence of the impact of weight-
related stigmatization in obese individuals at the social level and its consequences
in mental health. In the ICF framework,
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OBJECTIVES:The aim of our retrospective study was to analyze the further fracture
related treatment/complication after primary treatment of femur neck fracture
according to most frequently used types of operation. METHODS: The data derive
from the financial database of the Hungarian National Health Insurance Fund Ad-
ministration, based on the 10th revision of the International Classification of Dis-
eases (ICD) with ICD code S7200. The following patients were included into the
study: having social insurance identification number, being discharged from hos-
pitals in 2000 after primary treatment of femur neck fracture, over the age 60. The
patients with polytrauma or high energy trauma patient were excluded from the
study. During the 8 year follow up period the further fracture related treatment and
complications were analyzed according to the most frequently used types of
operation. RESULTS: Altogether 3783 patients were included into the study. The
distribution of primary surgical intervention was: arthroplasty 12.5%, screw fixa-
tion 73.6%, dynamic hip screw (DHS) 5.1%, femoral neck nailing 5.0%, Ender nailing
1.8%, Gamma nailing 1%, others 1 %. The fracture related treatment rate was 14,5%.
The main types of further fracture related treatments are listed: 5.7% hip replace-
ment, metalwork removal 3.6%, replacement of implants 2.48%, aseptic and septic
look: 1.7%, 0.7% resection arthroplasties. The further fracture related treatment
rate according to the most frequently used types of operation: arthroplasty 4.8 %,
screw fixation: 16.1 %, DHS: 7.8%, femoral neck nailing: 21.5%, Ender nailing: 19.4 %,
Gamma nailing: 2.4%. CONCLUSIONS: The methods, providing quickly full weight
bearing (Gamma nailing, DHS, hip arthroplasty) had lower complication rate, while
the methods (screw fixation, Ender nailing, femoral neck nailing) providing partial
weight bearing had higher complication rate. The backgrounds of fracture related
treatments should be investigated in the future.
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OBJECTIVES: Brain metastases occur in a majority of patients with malignant
disease and result in decreased quantity and quality of life. Treatment alterna-
tives range from whole brain radiation therapy (WBRT), neurosurgery, and the
newest modality, stereotactic radiosurgery (SRS). This article reviews economic
evaluations of SRS in the metastatic setting and compares to other treatment
options. METHODS: Studies were included if they were published in peer reviewed
journals, primarily in patients with malignant brain metastasis, and at least in-
cluded a cost analysis between interventions RESULTS: Uncertainty surrounding
the cost-effectiveness of SRS exits due to lack of efficacy information between
treatment alternatives, methodological limitations, and design differences be-
tween the available studies. However, when cost –effectiveness ratios are avail-
able, SRS appears to be a reasonable option in resource limited settings, with in-
cremental cost-effectiveness ratios (ICERS) just below the $50,000 range.
CONCLUSIONS: Better designed economic analysis in the setting of randomized
clinical trials or observational studies need to be conducted to fully understand the
economic value of SRS.
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OBJECTIVES: Thailand has been one of the leading developing countries to imple-
ment a national program to prevent mother-to-child transmission (PMTCT) of HIV.
The objective of this study was to determine the impact of pharmacist intervention
to monitor HIV-infected pregnant women. Pharmacist provided medication and
guideline information including phamacotherapeutic suggestion. METHODS: In
this research, retrospective study was employed with descriptive statistics using
average percentage frequency, making use of out-patients records of treatments in
HIV-infected pregnant women who informed about the benefits of taking antiret-
roviral (ARV) drugs for PMTCT, side effects of ARV drugs, importance of adherence
to drugs and the fact that HIV transmission to their infants can possibly occur
despite ARV use by pharmacist. RESULTS: The HIV-infected pregnant women
group of 24 cases, 4 were withdrawn due to unable to follow up, 20 cases have been
followed-up and shown the effectiveness of medicine. There were 8 new patients
(33.33%) firstly received ARV. The mean CD4 cell counts at baseline of all patients
were 227-69.28 cells/mm3. Most regimens for treatment was highly active anti-
retroviral therapy containing zidovudine (AZT)lamivudine (3TC)lopinavir/
ritonavir (LPV/rtv) 41.67% where treated with AZT3TCnevirapine were secondly
used (33.33%). It was found that 34.4% of patients had adverse drug reactions. The
ADR incidence of ARV was 4.0 patients and 6.2 events per 1000 person-day. Gas-
trointestinal system such as nausea and vomiting were found at 12.50% and 8.33%
were diarrhea were the most organ system affected. During the study period, 3
patients had to change ARV regimens because of ADRs. 16.67% were non-compli-
ance but less than 7 days at early period. The rate of MTCT of HIV was 8.33% after
monitoring for one year. CONCLUSIONS: The results indicated that a medication
monitoring and evaluating process by pharmacist associated with improved ratio-
nal used of drug in HIV-infected pregnant women. This project provides a founda-
tion for future quality improvement.
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OBJECTIVES: The aim of this study was to assess efficacy and safety of tenofovir
(TDF) as compared to other nucleot(s)ide analogues (NAs), i.e. lamivudine (LAM),
adefovir (ADV) and entecavir (ETV) in the treatment of chronic hepatitis B virus
(HBV) infection.METHODS:Assessment was based on randomized controlled trials
(RCTs) identified by means of systematic review, carried out according to the Co-
chrane Collaboration guidelines. Studies met the inclusion criteria if they directly
compared at least two of following interventions: TDF, LAM, ADV, ETV or placebo.
The electronic medical databases (EMBASE, MEDLINE, CENTRAL) were searched.
Two reviewers independently selected trials, assessed their quality and extracted
data. Mixed treatment comparison (MTC) was performed with WinBugs software. If
feasible, subgroup analyses were performed according to hepatitis B antigen e
(HBeAg) and or LAM resistance status. RESULTS: We identified 30 relevant studies
(6674 patients) with 12-144 weeks of follow-up . MTC showed that TDF increased
the chance of HBV DNA clearance at the end of treatment period as compared to
ADV (OR  13,16 [3,21; 54,20]), LAM (OR  61,09 [11,10; 503,78]) and ETV (OR  9,55
[1,53; 76,98]). Subgroup analysis in HBeAg-positive subjects revealed that TDV was
more effective than ADV (OR  21,60 [1,67; 285,40]) and LAM with respect to HBV
DNA clearance but no difference were found between TDV and ETV (OR  11,24
[0,53; 342,57). TDF showed similar efficacy to other NAs with respect to normaliza-
tion of alanine aminotransferase activity (ALT) and histological improvement. TDF
did not increase the risk of any and serious adverse events either in comparison
with PLC or with other NAs. The rates of ALT flares were similar in all groups.
CONCLUSIONS:TDF demonstrated the highest efficacy with respect to reduction of
viral load in patients with chronic HBV and maintained a very good safety profile.
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COMPARING THE EFFICACY AND TOLERABILITY OF ANTI-RETROVIRAL
THERAPY IN TREATMENT-NAÏVE HIV-1 INFECTED ADULTS: A SYSTEMATIC
REVIEW OF RANDOMIZED CLINICAL TRIALS AND BAYESIAN MIXED
TREATMENT COMPARISONS INCLUDING ATAZANAVIR/R, DARUNAVIR/R,
LOPINAVIR/R, AND EFAVIRENZ
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OBJECTIVES:A framework for comparative research is useful for health technology
assessment (HTA) and clinical decision making. The objective was to systemati-
cally assess efficacy and tolerability of 3rd agents, atazanavir/r (ATV/r) compared to
darunavir/r (DRV/r), lopinavir/r (LPV/r) and efavirenz (EFV), in treatment-naïve
HIV-1 infected adults. METHODS: A systematic literature search was conducted to
identify published randomized clinical trials (1-1-2000 to present), in which the
four anti-retroviral (ARV) treatments were used for these patients. Pooled esti-
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mates for virological response (VR; viral load levels50 copies/ml), immunorecov-
ery (change in CD4 cells/l from baseline to week 96), incidence of diarrhea, nausea
and rash were generated by Bayesian mixed treatment comparison (MTC). Point
estimates were reported with corresponding 95% credible intervals. RESULTS: In
total, 6 unique studies and 2 study extensions were included; consisting of 3 ATV/r,
1 DRV/r, 5 LPV/r, and 5 EFV treatment arms. Pooled MTC estimates for VR at week
48 were 77.7% (95%CrI: 74.1%-81.1%) for ATV/r, 76.4% (72.9%-79.7%) for EFV, 74.7%
(67.2%-81.2%) for DRV/r, and 72.5% (69.9%-75.0%) for LPV/r. The ratio of the propor-
tion of patients with VR at week 96 versus week 48 was estimated at ATV/r: 0.934
(0.872-0.999), DRV/r: 0.918 (0.807-1.041), EFV: 0.908 (0.834-0.981) and LPV/r: 0.878
(0.827-0.929). Immunorecovery was 254.9 (245.2-264.9) cells/l for LPV/r, 238.1
(219.5-257.0), 225.2 (209.6-241.3), and 206.1 (190.3-222.4) for DRV/r, ATV/r and EFV
respectively. The incidence of diarrhea was 10.7% (8.7%-12.8%) for LPV/r, compared
to 4.5% (2.3%-7.4%), 2.3% (0.3%-7.0%), and 2.1% (1.0%-3.7%) for DRV/r, EFV, and
ATV/r respectively. The incidence of nausea and rash did not differ markedly
among the treatments. CONCLUSIONS: The estimates for efficacy and tolerability
suggest all 4 ARV treatments are valuable options in treatment-naive HIV patients,
with ATV/r’s sustained viral response bringing added value. This MTC provides a
useful framework for ARV treatment comparison for HTA and clinical decision
making.
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OBJECTIVES:To systematically assess the clinical and economic burden of invasive
fungal infection (IFI) in Europe and to understand the value and treatment out-
comes of diagnostic and empirical therapeutic approaches. METHODS: A compre-
hensive literature review was conducted using PubMed/MEDLINE and EMBASE
(past 10 years) and relevant clinical societies (last 5 years) to identify epidemiology,
outcomes, and treatment trends focusing on invasive Aspergillus and Candida
infections using a defined protocol for inclusion/exclusion and data collection met-
rics. Clinical and economic burden outcomes described were incidence, mortality,
overall healthcare resource utilization, length of hospital stay, and costs for IFI.
RESULTS: Of 370 abstracts screened, 57 primary literature articles and 18 clinical
society abstracts met inclusion criteria providing data from 12 European countries.
No studies were identified in Eastern Europe and only two randomized, controlled
studies comparing pre-emptive to empirical treatment were found. IFI incidence
ranged from 3%-8% in empirical vs 8%-9% in pre-emptive treatment. Overall (IFI
attributable) mortality ranged from 5%-41% (0%-24%) and 2%-17% (0%-13%) for
non-comparative vs comparative studies, respectively. The highest mortality was
found among critically ill patients, pediatric, and those with hematologic malig-
nancies. The cost of IFI ranged from €8,351-€11,821 when evaluating hospitaliza-
tions and antifungals to €26,596-€49,216 when all direct costs for management
were included. Costs for antifungal therapy alone were €3,930-€7,314. The incre-
mental cost burden of IFI ranged from €10,530-€51,033 depending on the certainty
of infection (possible, probable, proven) and duration of follow up. CONCLUSIONS:
IFI represents a substantial clinical and economic burden in critically ill and im-
munocompromised patients in Europe. IFI may account for up to 24% of mortality
in these high risk populations and increase length of hospitalization by 20%. Dif-
ferentiation of outcomes for pre-emptive and empirical treatment strategies have
not been well defined and should be the focus of future clinical studies.
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OBJECTIVES: The aim of the study was to conduct secondary analyses of trial data
to determine whether taking famciclovir within 12 hours of first perceiving the
symptoms of genital herpes was related to decreased outbreak severity and im-
proved healing. METHODS: Data were derived from a double-blind, randomised,
active-controlled study of patient-initiated therapy comparing a 2-day course of
famciclovir with a 5-day course (total dose 1,50 mg in both courses) in adults with
genital herpes. Patients completed the Herpes Symptoms Checklist (HSC) on each
day of the five day study period. The proportion of patients healed (without lesions)
at day 5 was also determined. RESULTS: Data were available for 501 patients
(male  58.5%; mean age (sd)  39.2 (11.6) yrs). For the combined treatment
groups, patients who took their medication within 12 hours had significantly
lower HSC scores on day 1 (within 12 hours, median HSC6; above 12 hours,
median HSC8; Mann-Whitney U12,733.5, p0.05). Patients who took their
medication within 12 hours also had significantly lower HSC area under the
curve scores for the 5 day study period (AUC; within 12 hours, median HSC3.8;
above 12 hours, median HSC5.1; Mann-Whitney U12,751.0, p0.05). These
differences were not apparent for the treatment groups separately. There was a
significant association between the time at which the patients took their med-
ication and whether or not they were healed at day 5 for the combined sample
(Chi-square  4.95, p0.05). This finding was also observed for the 2-day treat-
ment group (Chi-square6.11, p 0.05) but not for the 5-day treatment group
(Chi-square0.49, p0.48). CONCLUSIONS: Taking famciclovir within 12 hours of
first becoming aware of genital herpes symptoms is associated with decreased
symptom severity and speed of healing. The 2-day treatment, when taken within
12 hours, is associated with a higher rate of healing by day 5.
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OBJECTIVES: In Turkey, lamivudine (LAM) is the only reimbursed antiviral (AV)
agent for the treatment of chronic hepatitis B (CHB) patients with HBV-DNA level
107 copies/mL. According to local reimbursement guideline, Tenofovir (TDF)
should be added in case of non-response at week24, or when viral resistance is
observed. This study aimed to compare the long-term clinical outcomes of enteca-
vir (ETV) with the current reimbursement approach (LAM monotherapy or LAM
with add-on TDF as rescue) in this patient subgroup. METHODS: Analysis popula-
tion included patients (n1000; 35% HBeAg-positive; 35 years old) without com-
pensated or decompensated cirrhosis (CC or DC) or hepatocellular cancer (HCC) at
model entry. Daily dose of AVs compared were (1) ETV 0.5mg, (2) LAM 100mg and (3)
LAM 100mg  add-on TDF 300mg when non-response or viral resistance occurs. A
decision-tree model with 5 parallel pathways for different levels of HBV-DNA with
a time horizon of 10 years was built. Major clinical outcomes included mortality
and life-years lost (LYL). RESULTS: Monotherapy with LAM during 10 years, re-
sulted in 198CC, 8.9DC and 66HCC cases . Addition of TDF to LAM in case of non-
response or viral resistance, reduced these cases to 78, 3.6 and 24 patients, respec-
tively. ETV treatment resulted in 24, 0.9 and 7.5 avoided cases of CC, DC and HCC,
respectively. While 108 deaths are estimated with LAM monotherapy (1,916LYL), in
the LAM plus TDF approach, the number of death will decrease to 44 (794LYL). ETV
treatment will further improve the results with additional avoidance of 15 deaths
(275LYL). The advantage of ETV is more prominent in HBeAg-positive patients (444
avoided LYL). CONCLUSIONS: ETV was found to be superior to both LAM mono-
therapy and LAM add-on TDF approaches in the treatment of CHB. Better clinical
outcomes may be expected with the introduction of ETV in this subgroup.
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OBJECTIVES: To indirectly compare the efficacy of telaprevir and boceprevir com-
bined with peginterferon/ribavirin in achieving sustained viral response (SVR) in
treatment-naïve and treatment-experienced patients with genotype 1 chronic
hepatitis C virus (HCV). METHODS: A systematic review of literature was con-
ducted in MEDLINE (January 2000-December 2010) to identify randomized con-
trolled trials and comparative open-label studies on the efficacy of pegylated inter-
feron (-2a and -2b)-ribavirin (PR)-based treatment in genotype 1 chronic HCV
patients. A Bayesian mixed treatment comparison (MTC), enabling indirect com-
parisons of interventions while respecting randomization, was performed on the
endpoint of SVR (HCV RNA undetectable at 24 weeks after end of treatment), as-
suming fixed study effects. For treatment-experienced patients, only previous re-
lapsers and partial responders were included, as no clinical results in prior null-
responders were available for boceprevir. RESULTS: Twelve publications were
identified and included in the systematic review and MTC. In treatment-naïve
patients, the odds ratio (OR) (posterior mean [95% credible interval]) for telaprevir
(12 weeks Response Guided Treatment (RGT) 24/48 weeks PR) and boceprevir (24
weeks  RGT 28/48 weeks PR) versus PR was respectively 3.76 [2.78-5.22] and 2.96
[2.23-4.01]. The OR for the indirect comparison of telaprevir versus boceprevir was
1.46 [0.89-2.25] (probability(OR1)0.931). In treatment-experienced patients, the
OR of telaprevir (12 weeks  48 weeks PR) and boceprevir (32 weeks  RGT 36/48
weeks PR) versus PR was respectively 12.56 [7.30-24.43] and 5.12 [2.90-10.30]. The OR
for the indirect comparison of telaprevir versus boceprevir was 2.70 [1.02-5.80]
(probability(OR1)0.978) for all patients, and 3.63 [1.12-8.97] and 1.39 [0.08-6.05]
for prior relapsers and partial responders respectively. CONCLUSIONS: In the ab-
sence of direct comparative head-to-head studies between telaprevir versus boce-
previr for the treatment of chronic HCV genotype 1 patients, MTC-based indirect
comparison suggests better efficacy for telaprevir in both treatment-naïve and
treatment-experienced patients compared to RGT boceprevir.
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A DECISION TREE MODEL COMPARING CLINICAL OUTCOMES OF TREATMENT
WITH TELBIVUDINE WITH OR WITHOUT “TENOFOVIR ADD-ON AS NEEDED”
AND LAMIVUDINE WITH OR WITHOUT “TENOFOVIR ADD-ON AS NEEDED” IN
THE TREATMENT OF CHRONIC HEPATITIS B INFECTION IN TURKEY
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OBJECTIVES: In Turkey, lamivudine (LAM) is the only reimbursed antiviral (AV)
agent for the treatment of chronic hepatitis B (CHB) patients with HBV-DNA level
107 copies/mL. Tenofovir (TDF) can be added when the patient does not respond at
week24, or viral resistance emerges. This study aimed to compare the long-term
clinical outcomes of telbivudine (ldt) with or without TDF add-on and LAM with or
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